...content" frameborder="0" scrolling="no" style="width:100%;height:900px;"> Selina Koch AstraZeneca plc Arcus Biosciences Bristol-Myers Squibb Co. I-Mab Biopharma Akeso Biopharma Surface Oncology Inc. Novartis AG Corvus Pharmaceuticals Inc. Tracon Pharmaceuticals Inc. Eli...

...subcutaneous anti-PD-1/PD-L1 antibody globally. Simcere holds commercialization rights to envafolimab in China for cancer while Tracon Pharmaceuticals Inc....

...of 85% to 87% with three independent evaluators. Progenics stock rose $0.50 (10%) to $5.67. Tracon...
...3D Medicines partner for PD-L1 antibody Alphamab Oncology Ltd. (HKEX:9966) and 3D Medicines Corp. granted Tracon Pharmaceuticals Inc....
...NASDAQ:TCON) development and commercialization rights in North America to envafolimab (KN035) for soft tissue sarcoma. Tracon...

...Malvern. Pa.) hired Jennifer Ellis as SVP, quality. She was head of quality assurance at Tracon Pharmaceuticals Inc....

...Tracon dose first solid tumor patient with anti-CD73 mAb I-Mab Biopharma (Shanghai, China) and partner Tracon Pharmaceuticals Inc....
...in a U.S. Phase I trial of anti-CD73 mAb TJD5 in solid tumors. I-Mab and Tracon...
...MAGE-A4 SPEAR T-cell therapy, MAGEA4 TCR Masiviera, masitinib (AB1010, masican, masipro) TJD5 AB Science S.A. Adaptimmune Therapeutics plc I-Mab Biopharma Kiyatec Inc. NIH Tracon Pharmaceuticals Inc. Ecto-5'-nucleotidase...

...but she declined to disclosed any specific indications or timelines related to the company's research. Tracon...
...implications in hematologic malignancies, but said the company had no further comment on the former Tracon...

...interim futility analysis of the Phase III TAPPAS trial to treat advanced or metastatic angiosarcoma. Tracon Pharmaceuticals Inc....
...alone. Carotuximab is a human chimeric mAb against endoglin (CD105; ENG). Brian Moy, Assistant Editor Carotuximab (IV TRC105) Tracon Pharmaceuticals Inc. Endoglin...

...NEEQ:430187) Vocimagene amiretrorepvec/extended release flucytosine (Toca 511/Toca FC) High-grade glioma Phase III interim data 1H19 Tracon Pharmaceuticals Inc....

...that trial is in September 2019. An interim analysis of TAPPAS is expected this quarter. Tracon Pharmaceuticals Inc....
...Progression-free survival (PFS); overall response rate (ORR) Status: Phase II data Milestone: NA Brian Moy Carotuximab (IV TRC105) Tracon Pharmaceuticals Inc. Endoglin...

...sector, joined the firm in 2008. He is a director at Allakos Inc. (NASDAQ:ALLK) and Tracon Pharmaceuticals Inc....